静脉与口服补铁治疗尿毒症患者肾性贫血的效果观察

Observation on the efficacy of intravenous and oral iron supplementation on renal anemia in patients with uremia

目的观察对比静脉与口服补铁治疗尿毒症患者肾性贫血的效果。方法选取2019年1月~2020年7月本院收治的尿毒症肾性贫血患者60例开展本研究,回顾病例,根据不同的治疗措施将60例患者分为对照组与观察组,每组各30例。前者采用口服右旋糖酐铁分散片治疗,后者采用静脉补蔗糖铁治疗,治疗8周后,对比两组患者血常规及铁代谢指标水平、不良反应发生率、治疗总有效率、生活质量评分。结果观察组Hb、Hct、SF、TSAT分别为(110.20±5.11)g/L、(41.29±2.00)%、(602.33±81.57)μg/L、(46.11±5.30)%,均高于对照组的(91.15±5.61)g/L、(31.57±1.91)%、(322.45±60.85)μg/L、(33.20±4.33)%,差异有统计学意义(P<0.05);不良反应发生率比较,观察组(3.3%)低于对照组(23.3%),差异有统计学意义(P<0.05);治疗总有效率比较,观察组(100.0%)高于对照组(83.3%),差异有统计学意义(P<0.05);生活质量评分比较,观察组(91.55±2.66)分高于对照组(82.37±3.95)分,差异有统计学意义(P<0.05)。结论在尿毒症肾性贫血患者中,静脉补铁治疗效果远优于口服补铁治疗,且用药不良反应较少,安全性较高,对提高患者生活质量具有重要作用,值得推广。

Objective To observe and compare the efficacy of intravenous and oral iron supplementation on renal anemia in patients with uremia.Methods A total of 60 patients with uremia and renal anemia admitted to our hospital from January 2019 to July 2020 were selected to carry out this research.After reviewing the cases,patients were divided into the control group(n=30)and the observation group(n=30)according to different treatment measures.The former was treated with oral iron dextran dispersible tablets,while the latter was treated with intravenous iron sucrose.After 8 weeks of treatment,the blood routine,iron metabolism index level,incidence of adverse reactions(ADRs),total efficacy rate of treatment and quality of life(QoL)scores of the two groups of patients were compared.Results Hb,Hct,SF and TSAT in the observation group were(110.20±5.11)g/L,(41.29±2.00)%,(602.33±81.57)μg/L and(46.11±5.30)%,higher than(91.15±5.61)g/L,(31.57±1.91)%,(322.45±60.85)μg/L and(33.20±4.33)%in the control group,with statistically significant differences(P<0.05).The incidence of ADRs in the observation group was 3.3%,lower than 23.3%in the control group,with statistically significant difference(P<0.05).The total efficacy rate in the observation group was 100.0%,higher than 83.3%in the control group,with statistically significant difference(P<0.05).The QOL score in the observation group was(91.55±2.66)points,higher than(82.37±3.95)points in the control group,with statistically significant difference(P<0.05).Conclusion In patients with uremia and renal anemia,the therapeutic efficacy of intravenous iron supplementation is much superior to oral iron supplementation,with fewer ADRs and higher safety,which plays an important role in improving patients′QOL and is worthy of promotion.